Qualigen Therapeutics, Inc.

Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. This edition of Tech Transfer Roundup focuses on oncology deals; the next edition will look at non-oncology de

Tumor-infiltrating lymphocytes have long been regarded as a promising modality for treating solid tumor cancers with cell therapy, but an ongoing challenge in tapping that potential has been manufactu

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Histogen’s Regenerative Medi

T-cell immunotherapy specialist Tmunity Therapeutics Inc. hopes to develop the first drug for a rare pediatric cancer called diffuse intrinsic pontine glioma (DIPG) after licensing global rights to